|
1
|
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
|
Endocrinology
|
2003
|
3.93
|
|
2
|
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.
|
Endocrinology
|
2002
|
2.13
|
|
3
|
Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway.
|
Endocrinology
|
2003
|
1.68
|
|
4
|
Gene expression profiling of cultured human islet preparations.
|
Diabetes Technol Ther
|
2004
|
1.42
|
|
5
|
GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.
|
Diabetes Metab Res Rev
|
2003
|
1.33
|
|
6
|
Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood.
|
Eur J Endocrinol
|
2002
|
1.28
|
|
7
|
Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion.
|
Diabetes
|
2005
|
1.24
|
|
8
|
Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets.
|
Diabetes
|
2005
|
0.97
|
|
9
|
The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects.
|
Eur J Endocrinol
|
2002
|
0.96
|
|
10
|
Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death.
|
J Cell Physiol
|
2004
|
0.96
|
|
11
|
GLP-1 inhibition of pancreatic islet cell apoptosis.
|
Trends Endocrinol Metab
|
2003
|
0.93
|
|
12
|
Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.
|
J Clin Pharmacol
|
2010
|
0.93
|
|
13
|
Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.
|
Diabetes Metab Res Rev
|
2005
|
0.93
|
|
14
|
3,5,3'-Triiodo-L-thyronine enhances the differentiation of a human pancreatic duct cell line (hPANC-1) towards a beta-cell-Like phenotype.
|
J Cell Physiol
|
2005
|
0.91
|
|
15
|
Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs.
|
J Mol Endocrinol
|
2005
|
0.87
|
|
16
|
Hepatocyte growth factor protects rat RINm5F cell line against free fatty acid-induced apoptosis by counteracting oxidative stress.
|
J Mol Endocrinol
|
2007
|
0.86
|
|
17
|
GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release.
|
J Lipid Res
|
2003
|
0.79
|
|
18
|
SWEET--where are we heading with international type 1 diabetes registries?
|
Pediatr Diabetes
|
2012
|
0.79
|
|
19
|
Insulin and glucose regulate the expression of the DNA repair enzyme XPD.
|
Mol Cell Endocrinol
|
2003
|
0.78
|
|
20
|
Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion.
|
Endocrinology
|
2002
|
0.77
|
|
21
|
The role of GLP-1 in the regulation of islet cell mass.
|
Cell Biochem Biophys
|
2004
|
0.77
|
|
22
|
Novel strategies for the pharmacological management of type 2 diabetes.
|
Trends Pharmacol Sci
|
2004
|
0.75
|